| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2021-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113244411-B |
| titleOfInvention |
Method for inducing CTL cell by gene modified oncolytic virus and application of CTL cell in tumor treatment |
| abstract |
The invention relates to a method for inducing CTL cells by using a genetically modified oncolytic virus and application of the CTL cells in tumor treatment. The invention prepares an oncolytic virus expressing IL-24 and a monoclonal antibody specifically aiming at PD-1. The use of the oncolytic virus together with a monoclonal antibody may be useful for the treatment of nasopharyngeal carcinoma. The combined use of the oncolytic virus and the monoclonal antibody can find that the combined use of the oncolytic virus and the monoclonal antibody has synergistic treatment effect and excellent application prospect. |
| priorityDate |
2021-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |